Collegium Reports Third Quarter Financial Results and Provides Corporate Update
- Xtampza® ER prescriptions grow by 49% in the third quarter
- FDA Approval of sNDA, including Comparative OxyContin Data
- Strong balance sheet provides cash runway into mid-2019
- Conference call scheduled for today at
4:30 p.m. ET
“We are encouraged by the continued adoption of Xtampza ER with consistent prescription growth during the third quarter,” said
“During the third quarter, our focus on operational execution enabled us to generate momentum with Xtampza ER. We are encouraged, but not satisfied with our accomplishments,” said
Recent Milestones
Commercial
- Prescriptions for Xtampza ER grew to 27,713 for the third quarter, a 49% increase over the second quarter of 2017.
- Prescribers of Xtampza ER grew to 5,300 since launch, including 1,266 new prescribers during the third quarter of 2017.
- Strengthened formulary position at numerous payers, including:
Cigna ,Humana Part D and United Healthcare commercial.
Corporate
- Strengthened our balance sheet by selling common stock through our ATM facility for gross proceeds of
$32.2 million (of which$9.8 million was received during the third quarter and$22.4 million was received in October).
Clinical
- With the recent approval of our sNDA, the updated Xtampza ER label, includes:
- OxyContin Comparative Data - The addition of comparative oral pharmacokinetic data, collected in two completed clinical studies evaluating the effect of physical manipulation by crushing Xtampza ER compared with the abuse-deterrent version of OxyContin (oxycodone hydrochloride extended-release tablets) and a control (oxycodone immediate-release (IR)),
- Oral Human Abuse Potential Study - Results of an oral human abuse potential study comparing intact and manipulated Xtampza ER to oxycodone IR were added to the label. This study demonstrated that the oral administration of chewed and intact Xtampza ER in the fasted state was associated with statistically lower mean Drug Liking and Take Drug Again Visual Analogue Scale scores compared with crushed immediate-release oxycodone. In addition, the Drug Liking and Take Drug Again scores were similar for Xtampza ER taken in the intact and chewed states,
- Oral Abuse Deterrent Claim - The addition of an oral abuse deterrent claim into the label that indicates that Xtampza ER has physicochemical properties that are expected to reduce abuse via the oral route. Xtampza ER is the only single agent oxycodone with this labelling.
- OxyContin Comparative Data - The addition of comparative oral pharmacokinetic data, collected in two completed clinical studies evaluating the effect of physical manipulation by crushing Xtampza ER compared with the abuse-deterrent version of OxyContin (oxycodone hydrochloride extended-release tablets) and a control (oxycodone immediate-release (IR)),
- Numerous publications and presentations to show the clinical differentiation between Xtampza ER and other extended-release opioids, including:
- Strong presence at PAINWeek 2017, including hosting two product theaters and presenting three clinical posters,
- “The comparative pharmacokinetics of physical manipulation by crushing of Xtampza ER compared with Oxycontin” (Pain Management,
September 2017 ), - “In Vitro Drug Release After Crushing: Evaluation of Xtampza ER and Other ER Opioid Formulations” (Clinical Drug Investigations,
September 2017 ).
- Strong presence at PAINWeek 2017, including hosting two product theaters and presenting three clinical posters,
Third Quarter 2017 Financial Results
Beginning in the third quarter of 2017, the Company determined that it has sufficient experience with Xtampza ER to use the sell-in method of recognizing revenue, instead of the sell-through method that was used in prior quarters. Therefore, the quarter ended
Net product revenues for Xtampza ER for the 2017 Quarter were
Net loss for the 2017 Quarter was
Research and development expenses were
Selling, general and administrative expenses were
Collegium had cash and cash equivalents of
As of
Financial Outlook
Based on our current operating plans, we believe that our existing cash resources, including proceeds from common stock sold under our ATM facility that were received in
Conference Call Information
Collegium will host a conference call and live audio webcast on
About
Collegium is a specialty pharmaceutical company focused on developing a portfolio of products that incorporate its proprietary DETERx® technology platform for the treatment of chronic pain and other diseases. The DETERx technology platform is designed to provide extended-release delivery, unique abuse-deterrent properties, and flexible dose administration options.
About Xtampza ER
Xtampza® ER is Collegium’s first product utilizing the DETERx technology platform. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the
LIMITATIONS OF USE
Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, and because of the greater risks of overdose and death with extended-release opioid formulations, reserve Xtampza ER for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain.
Xtampza ER is not indicated as an as-needed (prn) analgesic.
The Full Prescribing Information for Xtampza ER contains the following Boxed Warning:
WARNING: ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; and CYTOCHROME P450 3A4 INTERACTION; AND RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS
Addiction, Abuse, and Misuse
Xtampza ER exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Assess each patient’s risk prior to prescribing Xtampza ER and monitor all patients regularly for the development of these behaviors or conditions.
Life-Threatening Respiratory Depression
Serious, life-threatening, or fatal respiratory depression may occur with use of Xtampza ER. Monitor for respiratory depression, especially during initiation of Xtampza ER or following a dose increase.
Accidental Ingestion
Accidental ingestion of even one dose of Xtampza ER, especially by children, can result in a fatal overdose of oxycodone.
Neonatal Opioid Withdrawal Syndrome
Prolonged use of Xtampza ER during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life threatening if not recognized and treated, and requires management according to protocols developed by neonatology experts. If opioid use is required for a prolonged period in a pregnant woman, advise the patient of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available.
Cytochrome P450 3A4 Interaction
The concomitant use of Xtampza ER with all cytochrome P450 3A4 inhibitors may result in an increase in oxycodone plasma concentrations, which could increase or prolong adverse drug effects and may cause potentially fatal respiratory depression. In addition, discontinuation of a concomitantly used cytochrome P450 3A4 inducer may result in an increase in oxycodone plasma concentration. Monitor patients receiving Xtampza ER and any CYP3A4 inhibitor or inducer.
Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants
Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death.
- Reserve concomitant prescribing of Xtampza ER and benzodiazepines or other CNS depressants for use in patients for whom alternative treatment options are inadequate.
- Limit dosages and durations to the minimum required.
- Follow patients for signs and symptoms of respiratory depression and sedation.
IMPORTANT SAFETY INFORMATION
Xtampza ER is contraindicated in patients with: significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment; known or suspected gastrointestinal obstruction, including paralytic ileus; and hypersensitivity (e.g., anaphylaxis) to oxycodone.
Xtampza ER contains oxycodone, a Schedule II controlled substance. As an opioid, Xtampza ER exposes users to the risks of addiction, abuse, and misuse. As extended-release products, such as Xtampza ER, deliver the opioid over an extended period of time, there is a greater risk for overdose and death due to the larger amount of oxycodone present.
Potential serious adverse events caused by opioids include addiction, abuse, and misuse, life-threatening respiratory depression, neonatal opioid withdrawal syndrome, risks of concomitant use or discontinuation of cytochrome P450 3A4 inhibitors and inducers, risks from concomitant use with benzodiazepines or other CNS depressants, risk of life-threatening respiratory depression in patients with chronic pulmonary disease or in elderly, cachectic, or debilitated patients, adrenal insufficiency, severe hypotension, risks of use in patients with increased intracranial pressure, brain tumors, head injury, or impaired consciousness, risks of use in patients with gastrointestinal conditions, risk of use in patients with seizure disorders, withdrawal, risks of driving and operating machinery, and laboratory monitoring.
The most common AEs (>5%) reported by patients in the Phase 3 clinical trial during the titration phase were: nausea (16.6%), headache (13.9%), constipation (13.0%), somnolence (8.8%), pruritus (7.4%), vomiting (6.4%), and dizziness (5.7%).
For Important Safety Information including full prescribing information visit: http://www.xtampzaer.com/
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from the company's current expectations. Management's expectations and, therefore, any forward-looking statements in this press release could also be affected by risks and uncertainties relating to a number of other factors, including the following: our ability to obtain and maintain regulatory approval of our products and product candidates, and any related restrictions, limitations, and/or warnings in the label of an approved product; our plans to commercialize our product candidates and grow sales of our products; the size and growth potential of the markets for our products and product candidates, and our ability to service those markets; the success of competing products that are or become available; our ability to obtain reimbursement and third-party payor contracts for our products; the costs of commercialization activities, including marketing, sales and distribution; our ability to develop sales and marketing capabilities, whether alone or with potential future collaborators; the rate and degree of market acceptance of our products and product candidates; changing market conditions for our products and product candidates; the outcome of any patent infringement or other litigation that may be brought against us, including litigation with
Contact:
adasalla@collegiumpharma.com
Collegium Pharmaceutical, Inc. Unaudited Selected Consolidated Balance Sheet Information (in thousands) |
|||||
September 30, | December 31, | ||||
2017 | 2016 | ||||
Cash and cash equivalents | $107,611 | $153,225 | |||
Accounts receivable | 5,823 | 2,129 | |||
Inventory | 1,401 | 1,316 | |||
Prepaid expenses and other current assets | 4,061 | 1,905 | |||
Property and equipment, net | 1,632 | 1,038 | |||
Intangible assets, net | 1,877 | 2,103 | |||
Restricted cash | 97 | 97 | |||
Other long-term assets | 171 | 204 | |||
Total assets | $122,673 | $162,017 | |||
Accounts payable and accrued expenses | $24,250 | $17,985 | |||
Deferred revenue | — | 4,944 | |||
Other liabilities | 2,154 | 4,180 | |||
Stockholders’ equity | 96,269 | 134,908 | |||
Total liabilities and stockholders’ equity | $122,673 | $162,017 | |||
Collegium Pharmaceutical, Inc. Unaudited Condensed Statements of Operations (in thousands, except share and per share amounts) |
|||||||||||||||
Three months ended September 30, | Nine months ended September 30, | ||||||||||||||
2017 | 2016 | 2017 | 2016 | ||||||||||||
Product revenues, net | $11,950 | $408 | $17,682 | $408 | |||||||||||
Costs and expenses: | |||||||||||||||
Cost of product revenues | 553 | 29 | 1,501 | 29 | |||||||||||
Research and development | 2,069 | 3,254 | 6,378 | 11,617 | |||||||||||
Selling, general and administrative | 22,758 | 23,567 | 67,667 | 55,266 | |||||||||||
Total costs and expenses | 25,380 | 26,850 | 75,546 | 66,912 | |||||||||||
Loss from operations | (13,430 | ) | (26,442 | ) | (57,864 | ) | (66,504 | ) | |||||||
Interest income (expense), net | 167 | (2 | ) | 402 | (113 | ) | |||||||||
Net loss | ($13,263 | ) | ($26,444 | ) | ($57,462 | ) | ($66,617 | ) | |||||||
Loss per share–basic and diluted | ($0.45 | ) | ($1.13 | ) | ($1.95 | ) | ($2.85 | ) | |||||||
Weighted-average shares -basic and diluted | 29,753,043 | 23,460,340 | 29,517,396 | 23,334,558 | |||||||||||